Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8373921 | 0.78 | KDM4E (0.31) | KDM4ETSHRTDP1 | |
| SCHEMBL8160250 | 0.78 | KDM4E (0.31) | KDM4ETSHRTDP1 | |
| SCHEMBL8372984 | 0.78 | KDM4E (0.31) | KDM4ETSHRTDP1 | |
| SCHEMBL19961857 | 0.76 | KDM4E (0.33) | KDM4ETSHRTDP1 | |
| SCHEMBL8155340 | 0.75 | TSHR (0.37) | KDM4ETSHRTDP1 | |
| SCHEMBL8373916 | 0.75 | TSHR (0.37) | KDM4ETSHRTDP1 | |
| SCHEMBL8372103 | 0.75 | TSHR (0.37) | KDM4ETSHRTDP1 | |
| SCHEMBL8376417 | 0.73 | ALDH1A1 (0.36) | KDM4ETSHRTDP1 | |
| SCHEMBL8376565 | 0.73 | ALDH1A1 (0.36) | KDM4ETSHRTDP1 | |
| SCHEMBL8153898 | 0.73 | ALDH1A1 (0.36) | KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220010040-A1 | REMOVAL OF THIOCARBONYLTHIO END GROUPS FROM POLYMERS | UNIV KING ABDULLAH SCI & TECH (SA) | 2022-01-13 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | KDM4E 2596/4885TSHR 2756/4885TDP1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.